Vincristine sulfate liposomal - Luye Pharma Group
Alternative Names: LY 01609; Vincristine sulphate liposomal - Luye Pharma GroupLatest Information Update: 14 Jan 2022
Price :
$50 *
At a glance
- Originator Luye Pharma Group
- Class Antineoplastics; Vinca alkaloids
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 25 Jul 2016 Vincristine sulfate liposome is still in phase III trials for Acute lymphoblastic leukaemia (first-line therapy) in China (NCT02072785)
- 01 Jun 2013 Phase-III clinical trials in Acute lymphoblastic leukaemia (first-line therapy) in China (IV-injection)